Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis

A phase 2, open-label study in 21 patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis showed that tafamidis (20 mg daily for 12 months) stabilized these transthyretin variants. We assessed cardiac amyloid infiltration and cardiac abnormalities in this same study populat...

Descripción completa

Detalles Bibliográficos
Autores principales: Damy, Thibaud, Judge, Daniel P., Kristen, Arnt V., Berthet, Karine, Li, Huihua, Aarts, Janske
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382536/
https://www.ncbi.nlm.nih.gov/pubmed/25743445
http://dx.doi.org/10.1007/s12265-015-9613-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382536/
https://www.ncbi.nlm.nih.gov/pubmed/25743445
http://dx.doi.org/10.1007/s12265-015-9613-9

Ejemplares similares